-
-
-
-
-
-
-
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
-
-
-
-
-
-
-
Phathom Pharmaceuticals, Inc. (PHAT) Tops Q2 EPS by 12c
-
-
-
-
-
-
-
Phathom Pharmaceuticals, Inc. (PHAT) Tops Q4 EPS by 42c
-
-
-
-
-
-
-
Phathom Pharmaceuticals (PHAT) PT Raised to $12 at Goldman Sachs
-
-
-
-
-
-
-
Phathom Pharmaceuticals, Inc. (PHAT) Tops Q4 EPS by 27c
-
-
-
-
-
-
-
Bragar Eagel & Squire, P.C. Is Investigating Phathom, Reata, and Comerica and Encourages Investors to Contact the Firm
-
-
-
-
-
-
-
TOP RANKED ROSEN LAW FIRM Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
-
1,197,523 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

